At a glance
ClinicalIndex Comparison RecordPhase 3Recruiting· 1,200 target
Drug / intervention
Anlotinib plus the same Immune Checkpoint Inhibitors. +2 moredrug
Likely dose
Anlotinib plus the same Immune Checkpoint Inhibitors. 8mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Anlotinib With or Without Immune Checkpoint Inhibitors in Standard Chemo-immunotherapy Failed Advanced Non-small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating Anlotinib plus the same Immune Checkpoint Inhibitors., Anlotinib plus the new Immune Checkpoint Inhibitors., and 1 other intervention for Non-small Cell Lung Cancer. Currently recruiting, targeting 1,200 participants across 1 site.
Detailed Summary
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesChina
Collaborators--
Timeline
Phase 3Recruiting
2020202120222023202420252026202720282029
Enrollment StartMar 2020
First PostedMar 2020
TodayJul 2026
Primary CompletionMar 2028
Study CompletionMar 2029
First PostedMar 26, 2020
Enrollment StartMar 24, 2020
Primary CompletionMar 24, 2028
Study CompletionMar 24, 2029
TodayJul 1, 2026
Enrollment to primary: 8 yearsPosted 6.3 years agoPrimary completion in 1.7 years
Interventions
Anlotinib plus the same Immune Checkpoint Inhibitors.drug
Anlotinib, 8mg po qd, D1-D14 every 21days.
Anlotinib plus the new Immune Checkpoint Inhibitors.drug
Anlotinib, 8mg po qd, D1-D14 every 21days.
Anlotinibdrug
Anlotinib, 8mg po qd, D1-D14 every 21days.